The Effect of Retatrutide on Kidney Parameters in Participants With Type 2 Diabetes Mellitus and/or Obesity.

In both trials, participants with baseline UACR ≥ 30 mg/g had larger UACR reductions in the retatrutide groups than in the overall population, although the reductions did not reach statistical significance compared with placebo likely because of the small subgroups (T2D trial: n = 62; obesity trial: n = 33).

also in 111,027 other papers